Duavive conjugated estrogens/bazedoxifene regulatory update

The European Commission approved Duavive conjugated estrogens/bazedoxifene from Pfizer to treat estrogen deficiency symptoms in postmenopausal women with a uterus for whom progestin-containing therapy is inappropriate. Pfizer markets the drug in the U.S. as Duavee to treat moderate to severe vasomotor symptoms (VMS) associated with menopause in non-hysterectomized women and to prevent postmenopausal osteoporosis (see BioCentury, Oct. 14, 2013). ...